SUPPLEMENTARY FINANCIAL DATA (UNAUDITED)

12 Months Ended

Dec. 31, 2022

SUPPLEMENTARY FINANCIAL DATA (UNAUDITED)

SUPPLEMENTARY FINANCIAL DATA (UNAUDITED)

SUPPLEMENTARY FINANCIAL DATA

(UNAUDITED)

(In thousands, except per share data)

The following table presents certain unaudited consolidated quarterly financial information for the eight quarters in the periods ended December 31, 2022 and 2021. This information has been prepared on the same basis as the audited consolidated financial statements and includes all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the unaudited quarterly results of operations set forth herein. For all periods prior to the quarter ended September 30, 2022, the information below has been retroactively adjusted for discontinued operations presentation.

	For the Quarter Ended
	March 31,		June 30,		September 30,		December 31,
2022
Total revenue	$	13,196	$	11,050	$	12,451	$	14,649
Costs and expenses		51,698		37,929		21,595		32,081
Loss from operations		(38,502)		(26,879)		(9,144)		(17,432)
Net loss from continuing operations		(41,538)		(26,570)		(10,460)		(14,256)
Net income from discontinued operations		15,592		18,379		927,091		3,894
Net income (loss)		(25,946)		(8,191)		916,631		(10,362)
Net loss from continuing operations - basic and diluted per share		(0.55)		(0.35)		(0.21)		(0.21)
Net income from discontinued operations - basis and diluted per share		0.21		0.24		12.35		0.06
Net income (loss) - basis and diluted per share	$	(0.34)	$	(0.11)	$	12.14	$	(0.15)
2021
Total revenue	$	14,257	$	12,914	$	13,194	$	14,946
Costs and expenses		98,149		77,024		66,809		71,113
Loss from operations		(83,892)		(64,110)		(53,615)		(56,167)
Net loss from continuing operations		(86,490)		(64,856)		(55,910)		(57,814)
Net income from discontinued operations		6,811		12,451		20,602		25,780
Net loss		(79,679)		(52,405)		(35,308)		(32,034)
Net loss from continuing operations - basic and diluted per share		(1.35)		(0.99)		(0.76)		(0.78)
Net income from discontinued operations - basis and diluted per share		0.11		0.19		0.28		0.35
Net income (loss) - basis and diluted per share	$	(1.24)		(0.80)		(0.48)		(0.43)
Share of Total YUPELRI Net Sales (1)
	For the Quarter Ended
	March 31,		June 30,		September 30,		December 31,
2022	$	15,283	$	17,177	$	18,698	$	19,495
2021	$	12,908	$	14,621	$	13,806	$	15,344

(1) The Company co-promotes YUPELRI in the US under a profit and loss sharing arrangement with Viatris (65% to Viatris; 35% to Theravance Biopharma). The amounts represent the Company’s implied 35% share of the total net sales of YUPELRI that were recognized within Viatris’ financial statements for the periods presented.